The Oncotype DX test offers two important pieces of information:
In order to be classed as a predictive test, a multigene assay must be trialed in a two-arm study designed to show an interaction between the biomarker and the treatment groups, and the interaction must be statistically significant to show a positive outcome.6
Other multigene assays in early-stage breast cancer were designed to answer different questions and have not been proven to predict chemotherapy benefit. Clinical-pathological factors, whilst playing an important role in a patient’s diagnosis, are only proven to be prognostic.7
Only the Oncotype DX Breast Recurrence Score test was designed to be both prognostic and predictive, meaning it can help identify which patients need chemotherapy. Therefore, when ordering a genomic test to guide chemotherapy decisions for your patients with HR+, HER2-, early-stage breast cancer, only the Oncotype DX test provides a reliable, actionable answer. The test is backed by over 120,000 patients’ worth of data4,5,8-15 and recommended by all major guidelines16-23.
To place an order online, visit our physician portal.
